-
1 Comment
Polus BioPharm Inc is currently in a long term downtrend where the price is trading 0.0% below its 200 day moving average.
From a valuation standpoint, the stock is 56.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Polus BioPharm Inc's total revenue sank by 89.3% to $234M since the same quarter in the previous year.
Its net income has increased by 75.2% to $-1B since the same quarter in the previous year.
Finally, its free cash flow fell by 4.2% to $-812M since the same quarter in the previous year.
Based on the above factors, Polus BioPharm Inc gets an overall score of 2/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| Sector | |
| ISIN | KR7007630007 |
| Industry |
| Market Cap | 48B |
|---|---|
| PE Ratio | None |
| Beta | 1.48 |
| Target Price | None |
| Dividend Yield | 0.0% |
Polus BioPharm Inc. operates as a biopharmaceutical company in South Korea. Its products in pipeline includes PDP808, an insulin glargine biosimilar for treating diabetes; PDP805, a somatropin biosimilar used for treating growth hormone deficiency; PDP807, a ranibizumab biosimilar for the treatment of macular degeneration; and PDP815, an insulin lispro biosimilar used for treating diabetes. The company was formerly known as Amnis Co., Ltd. and changed its name to Polus BioPharm Inc. in December 2017. Polus BioPharm Inc. was founded in 1972 and is based in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 007630.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
